Komori
Governance4875MediciNova,Inc.Pharmaceuticals

Corporate Governance Report 2026/06/30

The company updated and disclosed its corporate governance structure as of 30 June 2026. Of the 5 directors, 3 are independent outside directors. The company has audit, compensation, nomination, and corporate governance committees, each composed solely of outside directors.

Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with a Nominating Committee, etc.
Controlling shareholder
No controlling shareholder

excluding the parent company). No parent company.

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Number of directors5, including 3 outside directors
Number of independent officers3Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Committee3
Audit CommitteeCompensation CommitteeNomination and Corporate Governance Committee
Percentage of outside members 3 outside members/3 members in total, 100%
Policy on cross-shareholdings

The company currently holds no shares for policy purposes.

Policy regarding shares of other companies held to maintain business relationships and for other purposes.

Takeover defenses

None (not adopted)

Pre-agreed countermeasures in preparation for an unsolicited takeover attempt.

Changes this time

No changes from the previous report are stated.

Governance structure
ItemDetails
Corporate Governance StructureCompany with a Nominating Committee, etc.
Number of directors5, including 3 outside directors
Number of independent officers3
CommitteeAudit Committee (3 outside members/3 members in total, 100%), Compensation Committee (3 outside members/3 members in total, 100%), Nomination and Corporate Governance Committee (3 outside members/3 members in total, 100%)
Policy on cross-shareholdingsThe company currently holds no shares for policy purposes.
Takeover defensesNone (not adopted)
Controlling shareholderNo controlling shareholder (excluding the parent company). No parent company.
Changes this timeNo changes from the previous report are stated.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

As a company listed on both the Japanese and US markets, to enhance the soundness and transparency of management and serve the interests of stakeholders. In addition, given the company's size and business profile, to balance the supervisory and advisory functions of outside directors and the various committees with more efficient execution of operations through the executive officer system.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/06/30 | MediciNova,Inc. (4875) timely disclosure | Komori